Strategies for Engineering Exosomes and Their Applications in Drug Delivery

Advancements in engineered exosomes for wound repair: current research and future perspectives

Wound healing is a complex and prolonged process that remains a significant challenge in clinical practice. Exosomes, a type of nanoscale extracellular vesicles naturally secreted by cells, are endowed with numerous advantageous attributes, including superior biocompatibility, minimal toxicity, and non-specific immunogenicity. These properties render them an exceptionally promising candidate for bioengineering applications. Recent advances have illustrated the potential of exosome therapy in promoting tissue repair. To further augment their therapeutic efficacy, the concept of engineered exosomes has been proposed. These are designed and functionally modifiable exosomes that have been tailored on the attributes of natural exosomes. This comprehensive review delineates various strategies for exosome engineering, placing specific emphasis on studies exploring the application of engineered exosomes for precision therapy in wound healing. Furthermore, this review sheds light on strategies for integrating exosomes with biomaterials to enhance delivery effectiveness. The insights presented herein provide novel perspectives and lay a robust foundation for forthcoming research in the realm of cutaneous wound repair therapies.

Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy

Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice.

Regulation of Extracellular Vesicle-Mediated Immune Responses against Antigen-Specific Presentation

Extracellular vesicles (EVs) produced by various immune cells, including B and T cells, macrophages, dendritic cells (DCs), natural killer (NK) cells, and mast cells, mediate intercellular communication and have attracted much attention owing to the novel delivery system of molecules in vivo. DCs are among the most active exosome-secreting cells of the immune system. EVs produced by cancer cells contain cancer antigens; therefore, the development of vaccine therapy that does not require the identification of cancer antigens using cancer-cell-derived EVs may have significant clinical implications. In this review, we summarise the molecular mechanisms underlying EV-based immune responses and their therapeutic effects on tumour vaccination.

"Targeting Design" of Nanoparticles in Tumor Therapy

Tumor-targeted therapy based on nanoparticles is a popular research direction in the biomedical field. After decades of research and development, both the passive targeting ability of the inherent properties of NPs and the active targeting based on ligand receptor interaction have gained deeper understanding. Unfortunately, most targeted delivery strategies are still in the preclinical trial stage, so it is necessary to further study the biological fate of particles in vivo and the interaction mechanism with tumors. This article reviews different targeted delivery strategies based on NPs, and focuses on the physical and chemical properties of NPs (size, morphology, surface and intrinsic properties), ligands (binding number/force, activity and species) and receptors (endocytosis, distribution and recycling) and other factors that affect particle targeting. The limitations and solutions of these factors are further discussed, and a variety of new targeting schemes are introduced, hoping to provide guidance for future targeting design and achieve the purpose of rapid transformation of targeted particles into clinical application.

Importance of two-dimensional cation clusters induced by protein folding in intrinsic intracellular membrane permeability

We investigated the cell penetration of Sp1 zinc finger proteins (Sp1 ZF) and the mechanism via which the total cationic charge and distribution of cationic residues on the protein surface affect intracellular trafficking. Sp1 ZFs showed intrinsic cell membrane permeability. The intracellular transfer of Sp1 ZFs other than 1F3 was dependent on the total cationic charge. Investigation of the effect of cationic residue distribution on intracellular membrane permeability revealed that the cellular uptake of unfolded Zn2+-non-coordinating Ala mutants was lower than that of the wild type. Therefore, the total cationic charge and distribution of cationic residues on the protein played crucial roles in intracellular translocation. Mutational studies revealed that the two-dimensional cation cluster on the protein surface significantly improved their cellular uptake. This study will contribute to the design of artificial cargoes that can efficiently transport target substances into cells.

Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system

Despite explosive growth in the development of nano-drug delivery systems (NDDS) targeting tumors in the last few decades, clinical translation rates are low owing to the lack of efficient models for evaluating and predicting responses. Microfluidics-based tumor-on-a-chip (TOC) systems provide a promising approach to address these challenges. The integrated engineered platforms can recapitulate complex in vivo tumor features at a microscale level, such as the tumor microenvironment, three-dimensional tissue structure, and dynamic culture conditions, thus improving the correlation between results derived from preclinical and clinical trials in evaluating anticancer nanomedicines. The specific focus of this review is to describe recent advances in TOCs for the evaluation of nanomedicine, categorized into six sections based on the drug delivery process: circulation behavior after infusion, endothelial and matrix barriers, tumor uptake, therapeutic efficacy, safety, and resistance. We also discuss current issues and future directions for an end-use perspective of TOCs.

Anti-Tumor Effect and Drug Delivery of Biomimetic Exosomes Nanoplatform Loading with Paclitaxel (PTX) for Treating Lung Adenocarcinoma

This study constructed an exosome (Exo) nanomedicine with the ability to actively penetrate into lung tumor tissue, in order to improve the anti-tumor effect of paclitaxel (PTX). For reaching this goal A549 lung adenocarcinoma cells were employed. The exosomes were collected by gradient centrifugation, and the Exo/PTX was prepared after targeted modification. Then the in vitro properties and in vivo tumor inhibitory effects of Exo/PTX were then characterized and evaluated. to conduct in vitro and in vivo study. The prepared Exo/PTX had a particle size of about 100 nm, and had a saucer-like double-layer membrane structure, which had a high encapsulation efficiency and drug loading. in vitro studies have shown that Exo/PTX can be largely taken up by lung cancer cells, thereby enhancing the drug’s effects on promoting apoptosis. The results of in vivo experiments showed that Exo/PTX can effectively inhibit the growth of tumor tissue. The results of this study showed that using exosome for drug delivery of PTX can increase the efficacy and decrease the drug toxicity and side effects.

Experimental Study on Antitumor Activity of Gold Nanoparticles-Assisted Delivery of PD-L1 SiRNA in Non-Small Cell Lung Cancer

Objective: By delivering PD-L1 siRNA to A549 cells using nano-gold we tried to enhance the lymphocytes’ ability to inhibit the growth of non-small-cell lung cancer. Methods: In a one-step reaction, gold nanoparticles and PD-L1 siRNA were combined to form gold nanoparticles and PD-L1 siRNA complexes. After incubation with A549 cells, PD-1 was detected by quantitative polymerase chain reaction (qPCR) as well as immunohistochemical staining. Mouse xenografts were used to test the anti-tumor activity. It was found that using a gold nanoparticle-siRNA complex, we were able to successfully reduce the expression of PD-L1 in A549 cells. The nano-gold-siRNA complex outperformed free siRNA after co-incubation with tumor cells. In vivo experiments show that nano-gold-siRNA is more effective at targeting tumor tissue and increasing T cells’ ability to inhibit the A549 tumor than free siRNA. For this study, we found that the delivery of siRNA to tumors using a nano-gold nanoparticle enhances the ability of the siRNA to aggregate in tumors, which in turn enhances the ability of T lymphocytes to combat non-small cell lung cancer by enhancing their anti-tumor activity. This nano-gold-PD-L1-siRNA complex may be a promising treatment for non-small cell lung cancer, according to preliminary results.

Metformin-Loaded Alginate Nanoparticles Inhibits Mouse Atherosclerosis by Regulating Macrophage Differentiation by Activating the Adenosine Monophosphate-Activated Protein Kinase/Signal Transducer and Activator of Transcription 3 Pathway

Objective: By modulating macrophage phenotype and the adenylate-activated protein kinase/signal transducer and activator of transcription 3 (STAT3) signaling pathway, metformin-loaded alginate nanoparticles may prevent atherosclerosis (As). Methods: Flow cytometry was used to determine the percentage of macrophages with distinct phenotypes (CD86 and CD206). Analysis of protein expression levels of iNOS, arginase 1, AMPK, pAMPK, STAT3 and phosphorylated STAT3 were performed by Western Blot. To confirm the in vitro findings, ApoE−/− mice were employed. Results: AMPK activity and the fraction of M2 macrophages dramatically increased in cells treated with Met, but STAT3 activity was considerably reduced. It was also shown that the Met group had much shorter aortas and lower levels of lipid deposition than that of the control group; also, the fraction of M1 macrophages in the lipid plaques of the animals treated with Met was dramatically reduced by using immunofluorescence labeling. There was a considerable increase in AMPK activity in the Met group, but STAT3 activity was dramatically lowered. Conclusion: According to the results of this study, STAT3 activity is regulated by activation of AMPK and macrophage development in plaques is prevented in mice by metformin-loaded alginate nanoparticles.